PolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Convention Name August 13, 2025 8:30 AM ET
Firm Contributors
Dikla Czaczkes Akselbrad – CEO & Director
Jonny Missulawin – Chief Monetary Officer
Ori Warshavsky – Chief Working Officer—US
Convention Name Contributors
Chase Richard Knickerbocker – Craig-Hallum Capital Group LLC, Analysis Division
Douglas Royal Buchanan – Residents JMP Securities, LLC, Analysis Division
Yehuda Leibler – Unidentified Firm
Operator
Greetings, and welcome to PolyPid’s Second Quarter 2025 Convention Name. [Operator Instructions] As a reminder, this name is recorded. And I’d now prefer to introduce your host for at the moment’s convention, Yehuda Leibler from ARX Capital Markets. Mr. Leibler, it’s possible you’ll start.
Yehuda Leibler
Thanks all for taking part in PolyPid’s Second Quarter 2025 Earnings Convention Name. Becoming a member of me on the decision at the moment will likely be Dikla Czaczkes Akselbrad, Chief Govt Officer of PolyPid; Jonny Missulawin, PolyPid’s Chief Monetary Officer; and Ori Warshavsky, Chief Working Officer, U.S. of PolyPid.
Earlier at the moment, PolyPid launched its monetary outcomes for the three months ended June 30, 2025. A replica of the press launch is out there within the Buyers part on the corporate’s web site accessible at www.polypid.com. I might prefer to remind you that on this name, administration will make forward-looking statements inside the that means of the federal securities regulation. For instance, administration is making forward- trying statements when it discusses D-PLEX100’s potential advantages, together with its potential to deal with a major unmet medical want and to considerably scale back the burden of surgical website infections, enhance affected person outcomes and generate significant well being care price financial savings, the anticipated regulatory submissions and their timing, the intention of GLP-1 program and its potential to deal with vital unmet medical wants within the therapy of metabolic ailments, the corporate’s anticipated money runway and the potential partnership alternatives for D-PLEX100.
Ahead-looking statements are topic to quite a few dangers and uncertainties, many
